POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle. |
| Excretion | Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion. |
| Half-life | The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism. |
| Protein binding | Potassium is not significantly protein-bound (<10%). Dextrose has negligible protein binding. No specific binding proteins identified for potassium; it exists as free ion in plasma. |
| Volume of Distribution | Potassium Vd is approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid. Total body potassium is ~50 mEq/kg, with 98% intracellular. The clinical meaning: initial dose distributes into ECF before equilibrating with ICF; rapid IV administration can cause transient hyperkalemia. |
| Bioavailability | Intravenous administration yields 100% bioavailability. Oral potassium chloride has ~90-100% bioavailability, but this formulation is not for oral use. Dextrose only given IV; not applicable for oral. |
| Onset of Action | Intravenous infusion produces immediate physiological effects, with ECG changes (e.g., T-wave normalization) occurring within minutes. Onset for potassium repletion depends on infusion rate; typically 30-60 minutes for measurable serum K+ increase. |
| Duration of Action | After cessation of IV infusion, serum potassium declines rapidly within 2-4 hours due to redistribution and renal clearance. The dextrose effect on glucose utilization lasts 1-2 hours post-infusion. Continuous infusion is needed for sustained repletion. |
| Molecular Weight | 74.55 |
Intravenous infusion; typical adult dose: 10-20 mEq per hour, not exceeding 40 mEq per dose and 200 mEq per day, titrated based on serum potassium and ECG monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-50 mL/min: reduce infusion rate by 25%; GFR 15-29: reduce rate by 50%; GFR <15: avoid use or use with extreme caution at reduced rate, monitor potassium closely. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor serum potassium and acid-base status closely in hepatic impairment due to risk of hyperkalemia. |
| Pediatric use | Intravenous infusion; 0.5-1 mEq/kg per dose, maximum 40 mEq per dose, infused at rate not exceeding 0.5-1 mEq/kg/hour; adjust based on serum potassium and clinical response. |
| Geriatric use | Use lower initial infusion rates (e.g., 5-10 mEq/hour) due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion. |
| 1st trimester | Potassium chloride and dextrose are generally safe in pregnancy when used as clinically indicated for electrolyte and fluid replacement. No known teratogenic effects. Monitor serum potassium and glucose levels closely. |
| 2nd trimester | Safe when used as indicated. Adjust infusion rates to avoid hyperkalemia or hyperglycemia, which may affect fetal well-being. |
| 3rd trimester | Safe with monitoring. Avoid excessive potassium to prevent maternal hyperkalemia and fetal arrhythmias. Dextrose may cause fetal hyperinsulinemia if maternal glucose rises excessively. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Potassium and glucose both cross the placenta. Potassium transfer is regulated by maternal-fetal gradients; excess may lead to fetal hyperkalemia. Glucose crosses via facilitated diffusion and can cause fetal hyperinsulinemia if maternal levels are high. |
| Breastfeeding | Potassium chloride and dextrose are endogenous substances. Potassium passes into breast milk at low levels and is not expected to cause adverse effects in nursing infants. Dextrose (glucose) is normally present in milk. Use with caution if maternal serum levels are abnormal (e.g., hyperkalemia, hyperglycemia) as this may alter milk composition. |
| Lactation Rating | L1 |
| Teratogenic Risk | No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No increased risk of congenital anomalies reported. However, maternal hyperkalemia or severe hypoglycemia may indirectly affect fetal well-being. |
| Fetal Monitoring | Monitor maternal serum potassium, glucose, electrolytes, and fluid balance during infusion. Fetal heart rate monitoring indicated if maternal condition unstable or if potassium administered for critical indications. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride or dextrose at therapeutic doses. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can lead to cardiac arrest.
| Serious Effects |
HyperkalemiaSevere renal impairment (anuria, oliguria, or acute renal failure)Hyperglycemia (uncontrolled diabetes, diabetic ketoacidosis without proper insulin coverage)Concurrent use of potassium-sparing diuretics (e.g., spironolactone, eplerenone) unless monitored closelySevere metabolic acidosisKnown hypersensitivity to potassium chloride or dextrose
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment, Cardiac monitoring recommended during infusion, Avoid rapid intravenous administration, Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders, May cause phlebitis at injection site |
| Food/Dietary | No specific food interactions with IV potassium chloride and dextrose. However, while on treatment, avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by your doctor, as concurrent dietary potassium may increase risk of hyperkalemia. |
| Clinical Pearls | Potassium chloride 0.3% in dextrose 5% provides 40 mEq/L of potassium and 50 g/L of dextrose. Administer via peripheral line; central line preferred for concentrations >40 mEq/L. Never give IV push. Infusion rate should not exceed 10 mEq/h or 200 mEq/24h without cardiac monitoring. Contraindicated in severe hyperkalemia, renal failure with oliguria, and untreated Addison's disease. Use with caution in patients with cardiac disease, digoxin therapy, or metabolic acidosis. Monitor serum potassium and ECG continuously during infusion. |
| Patient Advice | This medication is given through a vein to correct low potassium levels. · Report any pain, redness, or swelling at the IV site immediately. · You may experience increased thirst or urination due to the dextrose content. · Do not stop treatment abruptly without consulting your healthcare provider. · Inform your doctor of all medications you take, especially digoxin and diuretics. |
Loading safety data…